Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial -

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet Respiratory Medicine
Specialities: Cancers | Neurological disorders | Respiratory disorders
Summary
RCT (n=176) found that in patients with EGFR-mutant NSCLC and multiple brain metastases, icotinib was linked to significantly longer intracranial progression-free survival than whole-brain irradiation plus chemotherapy (10 vs. 4.8 months; HR 0.56, 95% CI, 0.36–0.90; p=0.014).
UKMi comment

Icotinib is an EGFR tyrosine kinase inhibitor approved in China and is currently in early phase trials outside China.
Related links: Comment